Showing results (181-190 of 214) with videos related to

Sort By:
Pageof 22
Bone Marrow Transplantation|February 9, 2016
Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomasF Heinzelmann, W Bethge, D W Beelen, et al.
ESMO Open|September 6, 2024
High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMTS Secondino, M Badoglio, G Rosti, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantationS K Metzelder, T Schroeder, M Lübbert, et al.
Leukemia|June 1, 2017
High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study groupB Kasenda, G Ihorst, R Schroers, et al.
Bone Marrow Transplantation|December 1, 2015
Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working PartyS P Robinson, A Boumendil, H Finel, et al.
Bone Marrow Transplantation|November 2, 2004
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosisR Saccardi, A Tyndall, G Coghlan, et al.
Leukemia|September 30, 2005
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)M Aoudjhane, M Labopin, N C Gorin, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|November 17, 2015
Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMTL Sellner, A Boumendil, H Finel, et al.
Bone Marrow Transplantation|November 8, 2016
Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMTM Robin, R Porcher, W Zinke-Cerwenka, et al.
Pageof 22